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This article describes the typical stages
in the analysis of microarray data for non-
specialist researchers in systems biology
and medicine. Particular attention is paid
to significant data analysis issues that are
commonly encountered among practition-
ers, some of which need wider airing.
The issues addressed include experimental
design, quality assessment, normalization,
and summarization of multiple-probe da-
ta. This article is based on the ISMB 2008
tutorial on microarray data analysis. An
expanded version of the material in this
article and the slides from the tutorial can
be found at http://www.people.vcu.edu/
,mreimers/OGMDA/index.html.
Introduction: Why Is Data
Analysis Still an Issue?
High-throughput methods are revolu-
tionizing biological research, and numer-
ous published articles describe innovative
insights obtained through analysis of
microarray data. Microarray technologies
are now available for measuring gene
expression, DNA copy number, methyla-
tion, chromatin state, protein binding,
SNPs, and other aspects of gene physiol-
ogy. To address the needs of many
biomedical researchers who do not often
have the resources to perform sophisticat-
ed data manipulation, several companies
and institutions have prepared pre-pack-
aged software to guide the researcher
through and perform all the steps of
standard microarray analysis. Commercial
packages include Genespring, Nexus (from
Biodiscovery), GeneSifter (from Geospiza),
Expressionist (from Genedata), Partek
Genomics Suite, and many others. Several
institutional packages are described at the
end of this article. With such packaged
software readily available, who really
needs to think about microarray analysis
or to collaborate with array analysis
specialists?
The premise of this review is that
innovative microarray analyses are rarely
straightforward and that most analyses
present problems and opportunities that
are not readily identified or adequately
addressed by packaged, comprehensive
software. For example, one common
problem in my experience is that com-
mon quality assessment (QA) practices
may be unable to eliminate all seriously
compromised chips. Furthermore, the
current best practices for expression
arrays don’t work well for many of the
new kinds of arrays (see Text S1, section
S2). Certainly, commercial software has
valuable uses; e.g., the quality and
flexibility of commercial graphics pro-
gramming for data visualization that
outstrips that of open-source software.
However, this review proposes a Malthu-
sian maxim for microarrays: that the
number of potential complications in
high-throughput biology grows exponen-
tially, while the expertise embodied in
packaged software has grown only linear-
ly. Thus, a researcher must know enough
about high-throughput methods to ascer-
tain when commercialized software can
be helpful and when an expert in micro-
array analysis should be consulted.
Most data analyses consist of the steps
outlined in Figure 1. This review will
follow these steps. The last two steps
(significance tests and biological interpre-
tation) and exploratory analysis are not
covered here. A complementary approach
to some of the early stages of a study was
presented recently in [1].
Experimental Design
Researchers know good data depends
on good experimental design. There are
several design issues that benefit from
statistical thinking, but the most promi-
nent issue is whether there will be enough
samples to find most of the genes that are
changed. Most researchers are aware of
the multiple comparisons issue; when they
perform a straightforward power calcula-
tion, they know to set the target signifi-
cance threshold much lower than it would
be for single tests. However, the actual
level of significance one would need to
detect a significant difference after stan-
dard Bonferroni multiple comparisons
adjustments to the p-value would be so
small that an experiment would require far
too many samples to be practical. For this
reason, in practice most researchers use
the false discovery rate (FDR) [2] to assess
significance in data analysis. It makes
sense, therefore, to perform power calcu-
lations using FDR, but such a calculation
is not so easy to perform. Another
approach to power estimation is to make
an analogy with published data to estimate
the power of one’s own study; such an
approach is implemented in the Micro-
array Power Atlas ([3] and http://www.
poweratlas.org).
A general principle of experimental
design is to make comparisons under
circumstances as closely matched as pos-
sible. A second issue that has tripped up
many researchers is that arrays processed
at different times or by different techni-
cians often show pronounced batch differ-
ences [4,5]. For example, there may be
different dynamic ranges in different
batches, or certain subsets of probes may
show greater signal independent of bio-
logical differences. Thus, it is important to
try to process all the arrays under as close
to identical conditions as possible, or, if
that is impossible, to randomize the
assignment of samples to processing times.
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In designing two-color array experi-
ments, the most common advice is to make
contrasts that are the most informative
[1,8]. Such a design helps to maximize the
information available in a fixed number of
arrays. For various reasons, such as flexi-
bility in the face of hybridization failures,
and in order to allow comparisons between
present and possible future experiments,
manyexperimenters chooseto co-hybridize
both case/treatment and control samples
with a common reference sample. In
keeping with the general principle in the
previous paragraph, it is better not to co-
hybridize samples that are expected to
differ markedly, because extreme ratios of
gene expression, far from one, usually have
much larger errors. Therefore, if one is
using a commonreference,itisbettertouse
a reference from a tissue similar to the
samples under study, rather than a refer-
ence from a different tissue.
Quality Assessment
Once an experiment has been designed
and performed, the next question is how to
decide which data are worth the effort to
analyze. Data are only as good as the
samples, and many researchers scrupu-
lously check RNA quality before hybrid-
ization. However, few researchers are able
to check the subsequent labelling and the
physical chemistry that occurs during
hybridization. In typical lab practice
focused on characterization of a single
gene, researchers draw on their experience
to optimize conditions for a particular
RNA target. However, it isn’t possible to
optimize conditions for all probes simulta-
neously on an array. Microarray measures
represent a dynamic balance among many
competing processes, and many factors
can shift these processes noticeably; for
example, the ratio of off-target hybridiza-
tion to true signal from each probe
depends on the relation among the
hybridization temperature, ionic strength,
and the thermodynamic characteristics of
the probe. Sometimes technical faults or
differences in technique peculiar to one
array can give very odd results without any
obvious indication in the QA metrics that
are routinely monitored in many labs. In
my experience with several labs at leading
institutions, arrays have slipped by with
particles of dust or scratches on a chip, air
bubbles in the hybridization, or wipe
marks (or even fingerprints!) on a glass
cover slip. These faults are often not visible
to the naked eye but can make a big
difference to data quality.
One general statistical approach to
address QA issues is to compare each chip
to an ideal reference and look for unusu-
ally large departures from the ideal that
seem correlated with known technical
variables [9–11]. In practice we don’t
know what the ideal reference values
should be, but for data sets drawn from
similar tissue types a robust mean of each
probe value across all arrays approximates
the ideal for that probe reasonably well. A
good way to look for technical faults is to
plot deviations of values on one chip from
their averages across many chips against
any technical variable [11]. For samples all
taken from one tissue type, most intensities
are roughly constant, and so average
probe intensity is a sensitive indicator of
probe saturation and quenching. Figure 2
shows a plot of log deviation against
average probe intensity. The average bias
is indicated as a function of intensity. Note
that the bias is very strongly negative for
the lower intensities; in fact, bias accounts
for much more difference from other chips
than all other sources of variation, which
includes biological differences. A well-
prepared array from an unusual sample
may well show substantial dispersion
around the bias curve, but the variation
in the bias curve will be smaller than the
standard deviation of the dispersion.
Some of the most striking images come
from representing variability across the
physical extent of a chip. Figures 3 and 4
Figure 1. Steps in a typical microarray
analysis.
doi:10.1371/journal.pcbi.1000786.g001
Figure 2. Plot of log ratio of intensity of an Affymetrix array. This plot represents
deviations of measures from chip GSM25526 (from GSE2552 in GEO) relative to the average across
all chips (on the vertical axis) plotted against that average (in log2 units on the horizontal axis) as
a technical variable. The black line indicates no trend; a loess fit to the trend is plotted in yellow.
Clearly, the deviation of the trend from 0 is bigger than the standard deviation of the variation
around the trend, a sign of a significant technical artifact.
doi:10.1371/journal.pcbi.1000786.g002
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the chip surface on an Agilent spotted
array and on an Illumina array. Figure S1
in Text S1 shows variation across spotted
arrays and on Affymetrix chips [9]. No
technology is immune from these kinds of
artifacts, although the measures from
multi-probe technologies, such as Affyme-
trix and Illumina, and to some extent
NimbleGen, are more robust to artifacts,
because many probes for a particular gene
will lie outside the area affected by a
regional artifact. A more sophisticated
approach to spatial variability, designed
specifically for Affymetrix arrays, uses the
idea of fitting a linear model to the profile
of each probe set separately. This ap-
proach eliminates from the QA metrics
differences between chips due to true
differences in gene expression, such as
those that occur in Figure 3. A ‘‘rogues’
gallery’’ of images from several public
Affymetrix data sets is at http://www.
plmimagegallery.bmbolstad.com/.
Numerous public domain tools exist for
quality assessment of array data. Bioconduc-
tor (http://www.bioconductor.org) features
several packages for Affymetrix, such as
affyQCReport, and for spotted arrays, such
as arrayQuality and arrayQualityMetrics.
Some code examples used in this paper will
be posted at http://www.people.vcu.edu/
,mreimers/OGMDA/index.html.
Normalization
Many researchers have tested reproduc-
ibility of array data by assaying the same
samples on the same platform at different
times or by employing different techni-
cians. The results are often unsettling;
when sample profiles from such studies are
compared, the technical differences are
often comparable to the biological differ-
ences [12]. Identification of key factors in
reproducibility is challenging because data
analysts generally don’t have access to
records of the procedures with sufficient
detail to identify crucial differences in
technique. And if such differences were
in fact known in advance, technicians
would attempt to minimize them. The
aim of normalization is to compensate the
measures for the effects of the differences
in procedures among the samples being
compared without delving into exactly
what the crucial technical differences
actually were.
A key decision researchers must make,
with consequences for normalization, is on
what scale to analyze their data. It is
common practice to transform to a
logarithmic (usually base 2) scale. The
principal motivation for this transforma-
tion is to make variation roughly compa-
rable among measures that span several
orders of magnitude. This often works as
intended; however, such a transformation
may actually increase variation of the low
intensity probes relative to the rest. In
particular, when a measure can be report-
ed as zero, the logarithm isn’t defined. A
simple remedy is to add a small constant to
the measures before taking the logarithm.
A more sophisticated approach is to use a
non-linear variance-stabilizing transform;
one such simple transform is f(x)=ln(( x +
(x
2+c
2)
1/2/2), where c is the ratio of the
constant portion of the variance to the rate
of increase of variance with intensity. For
more details and options, see [13–15].
A second major decision is whether to
use a background compensation, and if so,
which method to use. Many assays in
molecular biology, including early radio-
activity-based array assays for gene ex-
pression, show an ubiquitous background
signal, onto which is added specific signal
from the gene of interest. The situation
with microarrays is more complex. Some
kinds of scanners and dyes clearly show
luminescence across the whole array that
seems to be added onto the signals. This
kind of background can be estimated from
non-probe areas of a chip nearby each
probe. In many other types of array, the
probes seem to be completely opaque and
do not return luminescent signal from the
same causes as the surrounding areas. In
most arrays, cross-hybridization to probes
(which depends on the probe sequence) is
a bigger source of background than any
uniform physical cause, such as may be
inferred from the areas surrounding each
probe. In my experience, it is rare that a
simple background correction brings a
substantial improvement in accuracy (as
measured, say, by similarity of replicate
chips). Similar results were found by [16].
However, sometimes background com-
pensation may be advantageous, and in
those cases some methods are better than
others (see [16,17] for more details).
Once decisions about scale and back-
ground are made, researchers often com-
pare the overall distribution of measures
on their chips. For microarray pioneers in
the late 1990s, the most obvious differenc-
es between chips were that some arrays
had much brighter scans than others.
These differences in measures seemed
most likely due to technical differences
during the procedures rather than whole-
sale changes in gene expression; such
differences could be explained by varia-
tions in the amount of cDNA that was
hybridized, by differences in the efficiency
of the labelling reaction, and/or by
different scanner settings. The simplest
compensation for such technical differenc-
es was agnostic about the cause of the
Figure 3. False-color images of an Agilent array (AG1-Lab2-C1 from the MicroArray
Quality Control project). Green pixels represent probes whose value on this array is close to
their average values across all samples. Red pixels represent probes whose values are more than
1.41 (square root of 2) times their average values across all samples, while dark blue pixels
represent probes whose values are less than 0.71 (reciprocal of square root of 2) times those
averages.
doi:10.1371/journal.pcbi.1000786.g003
Figure 4. False-color image of an Illumina array. Colors represent how the signal from a
particular bead deviates from the average signal from that bead type across the array. The color
scale is as for Figure 3.
doi:10.1371/journal.pcbi.1000786.g004
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chip by the mean over that chip. This
normalization made the mean value of all
gene measures on each chip to be the
same; for two-color arrays, this normali-
zation made the average log ratio between
channels on the same chip to be zero.
Several variations on this procedure are
current: for example, Agilent recommends
that the 75th percentiles of intensity
distributions be aligned across arrays
[18]. This makes some sense if one thinks
that in a typical tissue about half the genes
are actually expressed; hence, the 75th
percentile would be the median of the
expressed genes. In our experience, align-
ing the 75th percentiles doesn’t actually
perform much better than aligning the
medians, and in fact loess or quantile
normalization (see below) are much better
[19,20].
The next development in array nor-
malization came in 2001 when Terry
Speed and co-workers noticed residual
bias in two-color log ratios depending on
average intensity; this bias could be seen
by plotting the log ratio (log(R)/log(G))
against the average brightness in the two
channels. The same bias can be seen in
one-color arrays by plotting the intensi-
t i e so no n ec h i pa g a i n s tt h ei n t e n s i t i e s
averaged across chips as a reference as
shown in Figure 2. Terry Speed and co-
workers [21] proposed estimating the
bias by a non-parametric curve, known
as a local regression (loess). The values of
log ratios are adjusted by subtracting the
estimated bias (the height of the loess
curve) at the same average brightness.
Such treatment improves most chips but
cannot fully compensate for an extreme
intensity-dependent bias such as that
shown in Figure 2. The method intro-
duced in [21] is now known as ‘‘loess
normalization’’. Loess normalization op-
erates on chips individually, but was
intended to make measures comparable
across chips as well. Further investigation
identified some biases between chips.
Hence, there is now a distinction be-
tween ‘‘within-chip’’ and ‘‘between-
chip’’ (or ‘‘across-chip’’) normalization.
Often, within-chip normalization may be
a first step before, or a part of, between-
chip normalization.
By 2003, statisticians were developing
more complex normalizations. Some stat-
isticians noticed that there were pro-
nounced differences in the loess curves fit
to log ratios in different regions of the same
chip;theytriedtofitseparateloess curvesto
each set of probes produced by a common
print tip of a robotically printed cDNA
array. Others tried to fit two-dimensional
loess surfaces over chips. Further compli-
cations included estimating a clone order
effect, and re-scaling variation within each
print-tip group [22,23]. In 2003, Benjamin
Bolstad, one of Terry Speed’s students,
proposedcuttingthroughallthecomplexity
by a simple non-parametric normalization
procedure, at least for one-color arrays
[24]. He proposed shoe-horning the inten-
sities of all probes on each chip into one
standard distribution shape, which is deter-
mined by pooling all the individual chip
distributions. The algorithm mapped every
value on any one chip to the corresponding
quantile of the standard distribution; hence
the method is called ‘‘quantile normaliza-
tion.’’ This simple between-chip procedure
worked aswellasmost ofthemore complex
procedures that were current at the time,
and certainly better than the regression
method, which was then the manufactur-
er’s default for Affymetrix chips. This
method was also made available as the
default in the affy package of Bioconductor,
which has become the most widely used
suite of freeware tools for microarrays (see
http://www.bioconductor.org). For all
these reasons, quantile normalization has
become the normalization procedure
which I see most often in papers.
While quantile normalization is a sim-
ple, fast, one-size-fits-all solution, it engen-
ders some problems of its own. For
example, the genes in the upper range of
intensity are forced into the same distri-
bution shape; such shoe-horning reduces
biological differences as well as technical
differences. A recent adjustment to the
quantile procedure in the latest versions of
the affy package fixes that problem. A
second issue is more subtle. For reasons
that are still not entirely clear, the errors in
different sets of probes are highly corre-
lated [12,25]. For probes for genes that are
in fact not expressed in the samples under
study, these correlated errors comprise
most of the variation among chips. When
quantile normalization acts on these
probes, the procedure preserves this ap-
parent but entirely spurious correlation
among low-intensity probes and some-
times seems to amplify that correlation.
Hence, sophisticated data mining methods
that depend on subtle analysis of correla-
tions may pick up spurious relationships
[26]. Finally, quantile normalization ex-
plicitly depends on the idea that the
distribution of gene expression measures
does not change across the samples. This
assumption is unlikely to be true when
testing treatments with severe effects on
the transcription apparatus or studying
cancer samples with severe genomic
aberrations.
Despite these problems, quantile nor-
malization seems to offer the best mix of
simplicity and effectiveness of all the
general methods for normalization that
have appeared in the past six years [19].
It is widely used for multiple-probe oligo-
nucleotide arrays, such as Affymetrix
arrays, where it is applied at the probe
level. Some people apply quantile normal-
ization at the summary level for Illumina
arrays [27]. In my experience, a quantile
normalization of both channels in a two-
channel microarray is at least as good as,
and sometimes better than, the standard
loess normalization for these arrays. Per-
haps the next stage in normalization will
need to address the technical causes of
variation. Since each kind of technical
variation affects many probes, such an
approach may also address the problem of
spurious correlations.
Recently, several papers have appeared
that address the issue of identifying and
compensating batch effects. The comBAT
method [5] uses an empirical Bayes
methodology: that is, it assumes that the
batch effects induce fairly similar devia-
tions in the majority of genes. In my
opinion, such an assumption is too strong.
However, the author provides an easy
software package in R to implement the
method. The method of [28] allows for
substantially different effects in different
genes, and infers a batch structure, which
may reflect differences in processing un-
known to the data analyst. The paper [28]
provides some compelling examples in the
field of the genetics of gene expression,
showing that systematic technical effects
lead to the (false) impression of systemic
biological effects, unless some correction is
performed, and suggests a method for
addressing such effects. The method of
[29] infers covariates, which may be
affecting many genes simultaneously, using
an algorithm related to principal compo-
nents analysis (PCA).
All of these methods indicate a renewed
interest in addressing systematic variation.
While these papers do not describe their
methods for compensating systematic ef-
fects as performing ‘‘normalization,’’ that
is in fact what normalization is supposed to
do: compensate systematic technical vari-
ation. In my opinion, several methods
under development will make this ap-
proach even more effective and accessible.
Naturally, I think two good ones will be
[30,31].
Summarization
The original idea behind the multiple
probe oligonucleotide arrays manufactured
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probes targeting a single gene (a ‘‘probe
set’’) yield many measures; in principle, the
average of those measures should give a
better estimate of gene expression than any
single measure. The reality is more com-
plex, and statisticians have enjoyed consid-
erable debate over how best to construct
single expression estimates based on multi-
ple-probe hybridization data. All of these
debates presume that the probes in a probe
set match a common unique transcript. In
light of current knowledge about splice
variation and alternate termination, that
assumption seems unlikely to be true,
although both Affymetrix and NimbleGen
did make a reasonable effort to design
probe sets to match the specific splice
variants that were known at the time of
their chips’ design. Hence, the signals from
one probe set may not all measure the same
population of transcripts. One way a user
can assess whether this is the case is to plot
measures from all probes of one probe set
across a set of samples. In my experience,
about half the Affymetrix probe sets show
consistent changes of all probes in a probe
set across samples. In recent years, several
authors have attempted to remap Affyme-
trix probes to ensure that all probes map to
the same transcript [32,33].
The ‘‘multi-chip’’ methods, such as
RMA (Robust Multichip Average), are
summarization schemes inspired by study-
ing the covariation of probes in a probe set
across a set of samples [34–36]. The
motivation for multi-chip methods comes
from reasoning that the signal from one
probe in a probe set should depend both on
the amount of that transcript in the sample
and on the specific affinity of the probe for
that transcript. Therefore, although probe
signals may differ on any one chip, the
signal from each probe should change by
the same factor between chips where the
amount of transcript in the samples differs.
Comparisons of processing algorithms
for oligonucleotide data have shown that
the multi-chip methods, which employ
comparisons of probe signals across chips,
generally havethebest signal-to-noise ratio.
There is still considerable debate over
exactly which multi-chip methods are
optimal. Rafael Irizarry has organized a
Web-basedcomparison tool,theAffyComp
project (http://affycomp.biostat.jhsph.
edu/ and [37]), based on high-quality
spike-in data sets published by Affymetrix.
In this comparison the gcRMA method,
which estimates the non-specific hybridiza-
tion background of each probe based on
sequence, comes out on top. In my opinion,
the very well-performed hybridizations
done in the manufacturer’s own facility
are not typical of results in most labs. In
particular, I see evidence that the pattern of
non-specific hybridization varies substan-
tially between chips in the same experi-
ment, for example by comparing the ratios
of PM and MM across chips. Furthermore,
when analyzing Affymetrix data produced
by typical core facilities, I often find more
variability between replicates when pro-
cessing the raw data by gcRMA than by
RMA. Therefore, I prefer to use the more
robust plain vanilla RMA.
Other Array Types
Many of the same issues (QA, normal-
ization, and summarization) arise for new
types of arrays; however, many of the
methods that have worked well for expres-
sion arrays don’t apply well to the new
array types. Some details of normalization
for several new array types are included in
the Text S1 section S2.
Next Steps
Most researchers want the chance to
explore their data, to discover unexpected
patterns beyond the ideas that informed the
studydesign.Twocommonlyusedmethods
are clustering and PCA. Clustering is useful
for discovering groups of genes with similar
expression patterns across a wide range of
biological conditions. Alternatively, cluster-
ing can be a first step toward identifying
molecular sub-types of a complex diagnosis
such as cancer [38]. Another exploratory
tool is PCA and its relative, correspondence
analysis [39,40]. These methods aim to
construct linear combinations of the vari-
ables (‘‘components’’) that can summarize
much of the information in all gene
measures across the samples. Space pre-
cludes an adequate discussion of these
approaches; for more information on
clustering, consult chapter 12 of [39] and
[41–43]. A nice package for multivariate
analysis specifically addressing microarray
data is MADE4 [44].
Often the goal of a study is either to
identify differentially expressed genes or to
make effective clinical predictions. Space
constraints prevent an adequate exposition
here of significance testing and the reader
is referred to [21,45–51].
There are a variety of important issues to
address in classification. Probably the best
single generalreference onthistopic is[52].
Prospects for the Next Five
Years
Both genomic technology and methods
for analysis are in rapid flux. Some issues,
such as normalization and summarization,
which are important for microarrays, may
be addressed by very different approaches
with the new technologies. Other issues
and approaches seem likely to be more
permanent, such as significance testing
and exploratory analysis.
Researchers are frequently interested in
biology that involves many types of mole-
cules, but DNA/RNA measures are the
most accessible with current technology.
So, when analyzing genomic data, many
researchers are looking at the shadows of
the biological processes of interest, e.g.,
protein activation, which may be better
reflected by another technology, e.g.,
protein arrays, when they become avail-
able. However, many of the same analysis
issues will arise when protein arrays finally
become operational. The technology will
be sufficiently different that we may need
some new methods for normalization.
However, it seems likely that many of the
methods worked out for assessing signifi-
cance of changes in genomic analysis will
apply directly to protein or other high-
throughput assays.
A current challenge for both basic
research and clinical investigation is the
integration of multiple data types: expres-
sion, genotype, and epigenetic data. All of
these may have relevance to predicting
clinical outcomes. A number of research-
ers are proposing methods for combining
these types of information [53].
Many researchers are enthusiastic about
the prospects for using high-throughput
sequencing (HTS) in genomic studies.
Some researchers expect that HTS tech-
nology will banish the shadows of technical
variability that have clouded microarray
studies. However, several studies suggest
that there is considerable technical vari-
ability even within the same lab [54], and
informal reports suggest considerable var-
iation between labs and between machines
in the same lab. Many of the data analysis
issues, which have arisen with microarray
technology, may be with us for a long time.
Practical Steps
If a researcher decides that in fact more
expertise is needed in experimental design
and subsequent analysis of array data, to
whom should she or he turn? Many
statisticians are becoming interested in
microarray data and may be able to give
advice on a project, or mentor a student
assistant. Furthermore, there is a great
deal of open-source and commercial
software for microarrays.
The largest single repository for open-
source software is the collection of Bio-
conductor packages [55,56] (http://www.
PLoS Computational Biology | www.ploscompbiol.org 5 May 2010 | Volume 6 | Issue 5 | e1000786bioconductor.org), which are written in
the R statistical programming language
(http://www.r-project.org). Several cours-
es on data analysis in R using the
Bioconductor tools are offered around
the world each year. Several commercial
software packages (e.g., GeneSpring) now
offer interfaces with Bioconductor. There
are also several freely available unified
suites of software, which include tools for
doing many of the functions described
here, including, TM4 (originally pro-
duced by The Institute for Genomic
Research, and now maintained by John
Quackenbush’s group at the Dana-Farber
Cancer Institute) at http://www.tm4.org;
BRBTools, maintained by the National
Cancer Institute (http://linus.nci.nih.
gov/BRB-ArrayTools.html); and GenePat-
tern from the Broad Institute (http://
www.broadinstitute.org/cancer/software/
genepattern/). The Robert S. Boas Center
for Genomics and Human Genetics pro-
vides a comprehensive survey of free
microarray software at http://www.nslij-
genetics.org/microarray/soft.html, and
Babru Samal maintains a list of free
and commercial software at http://
www.genetools.us/.
Supporting Information
Text S1
Found at: doi:10.1371/journal.pcbi.
1000786.s001 (0.31 MB DOC)
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